The Library
Comparing clinician and patient perspectives in the management of hot flushes in UK breast cancer patients
Tools
Tools
Tools
Morgan, A., Ah-See, M. L., Hunter, M., Armes, J., Filshie, J., Turner, L., Morris, C., Flint, M., Dunn, Janet A., Pennery, E., Sassarini, J., Stanway, S., Noble, J., Andreia, F., Morgan, D., Khambhaita, P. and Fenlon, D. (2017) Comparing clinician and patient perspectives in the management of hot flushes in UK breast cancer patients. BJOG-an International Journal of Obstetrics and Gynaecology, 124 (Supplement 1). pp. 100-102. HP114. doi:10.1111/1471-0528.7_14572
Research output not available from this repository, contact author.
Official URL: https://doi.org/10.1111/1471-0528.7_14572
Abstract
Introduction
Women who have been treated for breast cancer identify vasomotor symptoms, such as hot flushes and night sweats (HFNS), as a serious problem. An estimated 550 000 people live in the UK today with a diagnosis of breast cancer and up to 70% experience HFNS. Estrogen replacement remains the most effective treatment for hot flushes. However, this is contraindicated in the majority of women with estrogen‐dependent breast cancer. Fewer than 50% of women with estrogen receptor (ER) ‐positive breast cancer complete the recommended 5 years of endocrine treatment—tamoxifen and aromatase inhibitors (AIs). This lack of adherence leads to a 20% excess breast cancer mortality. This lack of adherence may be due to unacceptable side effects such as HFNS.
Objectives
Patient members of the National Cancer Research Institute UK Breast Clinical Studies Group identified that there is very little research into the management of symptoms after breast cancer treatment. In response we established a Working Party on Symptom Management. The members all have a particular interest in the management of HFNS, and include patients, as well as clinical and academic partners representing oncology, psychology, gynaecology, complementary therapies and the voluntary sector.
Methods
We gauged current clinical practice of the management of HFNS by surveying breast cancer patients, general practitioners (GPs) and healthcare professionals (HCPs) and we will present these data.
Results
Forty percent of patients reported that no HCPs or GPs had asked them about HFNS. Despite >90% of GPs and HCPs reporting that they prescribed drugs to alleviate HFNS, only 26% of the patients had been offered drugs and fewer than 2% said they helped; 31% of the patients said that the HFNS were severe enough for them to consider stopping endocrine therapy.
Conclusion
If women are to be helped to adhere to their life‐saving treatment, new approaches need to be developed to ameliorate HFNS.
| Item Type: | Journal Item | ||||
|---|---|---|---|---|---|
| Subjects: | R Medicine > RG Gynecology and obstetrics | ||||
| Divisions: | Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Clinical Trials Unit Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School |
||||
| Journal or Publication Title: | BJOG-an International Journal of Obstetrics and Gynaecology | ||||
| Publisher: | Wiley | ||||
| ISSN: | 1470-0328 | ||||
| Official Date: | March 2017 | ||||
| Dates: |
|
||||
| Volume: | 124 | ||||
| Number: | Supplement 1 | ||||
| Page Range: | pp. 100-102 | ||||
| Article Number: | HP114 | ||||
| DOI: | 10.1111/1471-0528.7_14572 | ||||
| Status: | Peer Reviewed | ||||
| Publication Status: | Published | ||||
| Access rights to Published version: | Restricted or Subscription Access | ||||
| Description: | Top Scoring Abstracts of the RCOG World Congress 2017, 20–22 March 2017, CTICC Cape Town, South Africa |
||||
| Related URLs: |
Request changes or add full text files to a record
Repository staff actions (login required)
 |
View Item |
